The Europe systemic aspergillosis and systemic candidasis market is projected to reach US$ 2,237.55 million by 2027 from US$ 1,702.60 million in 2019; it is estimated to grow at a CAGR of 3.5% from 2020 to 2027.
The market growth is primarily attributed to rise in the prevalence of fungal diseases and hospital-acquired fungal infections. Moreover, the COVID-19 pandemic has highly affected countries in Europe, further affecting the systemic aspergillosis and systemic candidasis market in the region.
Candida auris is a fungus that causes serious health threats; it has been reported to cause severe illness in hospitalized patients in several countries, including the UK. The fungus can continue to colonize within patients’ body, including different anatomical sites such as skin, axilla, and rectum, for a long period; it can also persist on hospital equipment and surfaces. The prolonged colonization might further result in the spread of C. auris among patients admitted in respective healthcare facilities. The emergence of this fungus is considered as one of the most serious problems associated with nosocomial transmission and with infection control practices in the hospital environment. For instance, as per the study published by the Centers for Disease Control and Preventions (CDC) in September 2019, C. auris was isolated in seven cases in Germany during 2013–2017, and six of these 7 were from patients who had history of hospitalized in foreign countries.
According to an NCBI report published in January 2020, the increasing number of tourists to foreign countries and exposure to healthcare facilities in countries with extensive C. auris transmission, as well as the higher flow of migrants, are factors that can contribute to the quick dissemination of this species. Further, the frequency of finding C. auris in public hospitals is greater than that is the private ones, which may be associated with overcrowding and compromised infection control measures. Thus, the rising hospital-acquired fungal infection incidence is creating demand for drugs for treating systemic aspergillosis and systemic candidiasis.
In 2019, the systemic oral azoles accounted for the largest share of the systemic aspergillosis and systemic candidasis market, based on type. The segment is expected to register the highest CAGR in the market during the forecast period on the back of advancements in systemic antifungal therapies. For instance, fluconazole has the most attractive pharmacologic (pharmacokinetics and pharmacodynamic) profile, exhibiting the capacity to maintain high concentrations of active drug in cerebrospinal fluid and urine.
A few of the major primary and secondary sources associated with this report on the Europe systemic aspergillosis and systemic candidasis market are the US Food and Drug Administration (FDA), National Library of Medicine – National Institutes of Health, and CDC.